Abstract Background & Aims Diagnostic criteria for metabolic associated fatty liver disease
(MAFLD) have been proposed, but not validated. We aimed to compare the diagnostic …

Background & aims This study aimed to evaluate risk factors associated with liver fibrosis in
metabolic dysfunction–associated fatty liver disease (MAFLD). Methods A cross-sectional …

Background and Aims Metabolic associated fatty liver disease (MAFLD) is diagnosed in
patients with hepatic steatosis when they have the following three metabolic conditions …

Abstract Background and Aims Recently metabolic dysfunction–associated fatty liver
disease (MAFLD) has been introduced and was defined as hepatic steatosis with either …

Background and aims Metabolic associated fatty liver disease (MAFLD) is a novel concept
proposed in 2020, the utility of which has not been tested and validated in real world. We …

Background Non-alcoholic fatty liver disease (NAFLD) is increasingly widespread with an
overall global estimated prevalence of 25%. Type 2 diabetes Mellitus (T2DM) is a key …

Patients with nonalcoholic fatty liver disease (NAFLD) and advanced liver fibrosis are at the
highest risk for progressing to end‐stage liver disease. We constructed and validated a …

Objective Knowledge of the epidemiology of non-alcoholic fatty liver disease (NAFLD) is
incomplete because liver biopsy cannot be performed on the general population to assess …

Background & Aims Fibrosis affects prognoses for patients with nonalcoholic fatty liver
disease (NAFLD). Several non-invasive scoring systems have aimed to identify patients at …

The detection of fibrosis within nonalcoholic fatty liver disease (NAFLD) is important for
ascertaining prognosis and the stratification of patients for emerging therapeutic …